{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:14:44Z","timestamp":1790972084078,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["CA224319"],"award-info":[{"award-number":["CA224319"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor-infiltrating T cells have been the primary focus of cancer immunotherapy; however, accumulating evidence points to a critical role for B cells and plasma cells in shaping responses to immune checkpoint blockade. In this study, we investigated the humoral immune response in 38 patients with hepatocellular carcinoma treated with neoadjuvant anti-programmed cell death protein 1 (PD-1) therapy. In responders, defined by more than 50% tumor necrosis, we observed on-treatment enrichment of clonally expanded IgG1\n                    <jats:sup>+<\/jats:sup>\n                    plasma cells within the tumor. Clonal tracking revealed that anti-PD-1 treatment expanded preexisting B cell clones associated with favorable clinical outcomes. Moreover, serum from responders contained IgG1 antibodies specific to cancer\/testis antigens, including NY-ESO-1, and these humoral responses were linked to tumor-reactive T cell activity. We independently validated these findings across seven additional cohorts, encompassing single-cell and bulk sequencing data from 500 patients, spatial transcriptomics from seven patients and survival analyses from 1,582 patients. Our findings apply to recently approved treatments, such as PD-1 and vascular endothelial growth factor A (VEGF-A) blockade, but not to chemotherapy alone, suggesting broad relevance to individuals treated with immunotherapy. Collectively, our results demonstrate that PD-1 blockade induces tumor-specific IgG1\n                    <jats:sup>+<\/jats:sup>\n                    plasma cell responses that complement cellular immunity and contribute to clinical benefit, underscoring a coordinated humoral\u2212cellular axis in effective antitumor immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04177-6","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:02:31Z","timestamp":1769508151000},"page":"978-991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade"],"prefix":"10.1038","volume":"32","author":[{"given":"Edgar","family":"Gonzalez-Kozlova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-7080","authenticated-orcid":false,"given":"Kevin","family":"Tuballes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5636-4709","authenticated-orcid":false,"given":"Sinem","family":"Ozbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6776-1635","authenticated-orcid":false,"given":"Pauline","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-7605","authenticated-orcid":false,"given":"Giorgio","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-9035","authenticated-orcid":false,"given":"Yohei","family":"Nose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-8735","authenticated-orcid":false,"given":"Ruiwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-2357","authenticated-orcid":false,"given":"Paula","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-3474","authenticated-orcid":false,"given":"Mark","family":"Buckup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Roudko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-2704","authenticated-orcid":false,"given":"Clotilde","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Le Berichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3769-5956","authenticated-orcid":false,"given":"Nicholas","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-7012","authenticated-orcid":false,"given":"Laszlo","family":"Halasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2529-9267","authenticated-orcid":false,"given":"Leanna","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Tabachnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-7220","authenticated-orcid":false,"given":"Christie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3959-0945","authenticated-orcid":false,"given":"Amanda","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-1635","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Mattiuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Eikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6983-5362","authenticated-orcid":false,"given":"Diane Marie","family":"Del Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Ruth","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson M.","family":"LaMarche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajra","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Lansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarod","family":"Morgenroth-Rebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Merand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6866-7502","authenticated-orcid":false,"given":"Bryan","family":"Villagomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Radkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7403-7015","authenticated-orcid":false,"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-9856","authenticated-orcid":false,"given":"Yasuko","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-9807","authenticated-orcid":false,"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Fiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Tabrizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Gunasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-9501","authenticated-orcid":false,"given":"Alice O.","family":"Kamphorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-6368","authenticated-orcid":false,"given":"Maria","family":"Curotto de Lafaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hapanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5610-6349","authenticated-orcid":false,"given":"Nicola","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-886X","authenticated-orcid":false,"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fiaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-4400","authenticated-orcid":false,"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9520","authenticated-orcid":false,"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4177_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"4177_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P. & Nelson, B. H. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat. Rev. Cancer 22, 414\u2013430 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"4177_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"4177_CR4","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","volume":"24","author":"MCA Wouters","year":"2018","unstructured":"Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125\u20136135 (2018).","journal-title":"Clin. Cancer Res."},{"key":"4177_CR5","doi-asserted-by":"publisher","first-page":"990463","DOI":"10.3389\/fimmu.2022.990463","volume":"13","author":"H Sui","year":"2022","unstructured":"Sui, H. et al. Immunotherapy of targeting MDSCs in tumor microenvironment. Front. Immunol. 13, 990463 (2022).","journal-title":"Front. Immunol."},{"key":"4177_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell\u2212CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"4177_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466\u2013489 (2023).","journal-title":"Cancer Cell"},{"key":"4177_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"4177_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"4177_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griss","year":"2019","unstructured":"Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).","journal-title":"Nat. Commun."},{"key":"4177_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289\u2013300 (2022).","journal-title":"Cancer Cell"},{"key":"4177_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"4177_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-23-3325","volume":"84","author":"G Petroni","year":"2024","unstructured":"Petroni, G., Pillozzi, S. & Antonuzzo, L. Exploiting tertiary lymphoid structures to stimulate antitumor immunity and improve immunotherapy efficacy. Cancer Res. 84, 1199\u20131209 (2024).","journal-title":"Cancer Res."},{"key":"4177_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4177_CR15","doi-asserted-by":"publisher","first-page":"20410","DOI":"10.1073\/pnas.0810114105","volume":"105","author":"J Yuan","year":"2008","unstructured":"Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 20410\u201320415 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4177_CR16","doi-asserted-by":"publisher","first-page":"16723","DOI":"10.1073\/pnas.1110814108","volume":"108","author":"J Yuan","year":"2011","unstructured":"Yuan, J. et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108, 16723\u201316728 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4177_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","volume":"189","author":"C Germain","year":"2014","unstructured":"Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832\u2013844 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4177_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron, T. U. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 219\u2013229 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4177_CR19","doi-asserted-by":"publisher","unstructured":"Buckup, M. et al. Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01475-9 (2025).","DOI":"10.1038\/s41551-025-01475-9"},{"key":"4177_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2022","unstructured":"Kudo, M. et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 12, 238\u2013250 (2022).","journal-title":"Liver Cancer."},{"key":"4177_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns, S. et al. PD-1\u2212CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat. Commun. 14, 7825 (2023).","journal-title":"Nat. Commun."},{"key":"4177_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36, 418\u2013430 (2019).","journal-title":"Cancer Cell"},{"key":"4177_CR23","doi-asserted-by":"publisher","first-page":"14467","DOI":"10.1073\/pnas.0405947101","volume":"101","author":"M Matsuo","year":"2004","unstructured":"Matsuo, M. et al. IFN-\u03b3 enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc. Natl Acad. Sci. USA 101, 14467\u201314472 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4177_CR24","first-page":"3","volume":"13","author":"A Gupta","year":"2013","unstructured":"Gupta, A. et al. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun. 13, 3 (2013).","journal-title":"Cancer Immun."},{"key":"4177_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"4177_CR26","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"4177_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"4177_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160\u2013171 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"4177_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.it.2022.01.003","volume":"43","author":"D Morgan","year":"2022","unstructured":"Morgan, D. & Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 43, 210\u2013229 (2022).","journal-title":"Trends Immunol."},{"key":"4177_CR30","doi-asserted-by":"publisher","first-page":"e153454","DOI":"10.1172\/JCI153454","volume":"132","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment.J. Clin. Invest. 132, e153454 (2022).","journal-title":"J. Clin. Invest."},{"key":"4177_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41591-018-0309-y","volume":"25","author":"Y Gu","year":"2019","unstructured":"Gu, Y. et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat. Med. 25, 312\u2013322 (2019).","journal-title":"Nat. Med."},{"key":"4177_CR32","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594\u20131609 (2021).","journal-title":"Cancer Cell"},{"key":"4177_CR33","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","volume":"117","author":"Y Iwata","year":"2011","unstructured":"Iwata, Y. et al. Characterization of a rare IL-10\u2013competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530\u2013541 (2011).","journal-title":"Blood"},{"key":"4177_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 616, 563\u2013573 (2023).","journal-title":"Nature"},{"key":"4177_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie, D., Ben-Shmuel, A., Erez, N. & Scherz-Shouval, R. Cancer-associated fibroblasts in the single-cell era. Nat. Cancer 3, 793\u2013807 (2022).","journal-title":"Nat. Cancer"},{"key":"4177_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/all.15601","volume":"78","author":"CJ Aranda","year":"2023","unstructured":"Aranda, C. J. et al. IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases. Allergy 78, 752\u2013766 (2023).","journal-title":"Allergy"},{"key":"4177_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj7412","volume":"379","author":"C Mlynarczyk","year":"2023","unstructured":"Mlynarczyk, C. et al. BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Science 379, eabj7412 (2023).","journal-title":"Science"},{"key":"4177_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev.immunol.21.120601.141138","volume":"21","author":"KL Calame","year":"2003","unstructured":"Calame, K. L., Lin, K.-I. & Tunyaplin, C. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21, 205\u2013230 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"4177_CR39","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-19-3211","volume":"26","author":"SS Kim","year":"2020","unstructured":"Kim, S. S. et al. B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade. Clin. Cancer Res. 26, 3345\u20133359 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4177_CR40","doi-asserted-by":"publisher","first-page":"689270","DOI":"10.3389\/fimmu.2021.689270","volume":"12","author":"W Kang","year":"2021","unstructured":"Kang, W. et al. Tertiary lymphoid structures in cancer: the double-edged sword role in antitumor immunity and potential therapeutic induction strategies. Front. Immunol. 12, 689270 (2021).","journal-title":"Front. Immunol."},{"key":"4177_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"4177_CR42","doi-asserted-by":"publisher","first-page":"e010541","DOI":"10.1136\/jitc-2024-010541","volume":"13","author":"V Roudko","year":"2025","unstructured":"Roudko, V. et al. Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. J. Immunother. Cancer 13, e010541 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"4177_CR43","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jtho.2019.08.008","volume":"14","author":"Y Ohue","year":"2019","unstructured":"Ohue, Y. et al. Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-programmed cell death-1 therapy in NSCLC. J. Thorac. Oncol. 14, 2071\u20132083 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"4177_CR44","doi-asserted-by":"publisher","first-page":"e17990","DOI":"10.1097\/MD.0000000000017990","volume":"98","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. NY-ESO-1 expression in solid tumors predicts prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 98, e17990 (2019).","journal-title":"Medicine (Baltimore)"},{"key":"4177_CR45","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","volume":"11","author":"AO Gure","year":"2005","unstructured":"Gure, A. O. et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11, 8055\u20138062 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4177_CR46","first-page":"11","volume":"7","author":"EF Velazquez","year":"2007","unstructured":"Velazquez, E. F. et al. Expression of the cancer\/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)\u2013correlation with prognostic factors. Cancer Immun. 7, 11 (2007).","journal-title":"Cancer Immun."},{"key":"4177_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-025-09188-4","volume":"644","author":"Y Dai","year":"2025","unstructured":"Dai, Y. et al. Humoral determinants of checkpoint immunotherapy. Nature 644, 527\u2013536 (2025).","journal-title":"Nature"},{"key":"4177_CR48","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1158\/2159-8290.CD-21-1658","volume":"12","author":"D Hao","year":"2022","unstructured":"Hao, D. et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. 12, 2626\u20132645 (2022).","journal-title":"Cancer Discov."},{"key":"4177_CR49","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.immuni.2022.11.014","volume":"56","author":"R-Q Wu","year":"2023","unstructured":"Wu, R.-Q. et al. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity 56, 180\u2013192 (2023).","journal-title":"Immunity"},{"key":"4177_CR50","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101044RRR","volume":"35","author":"X Luan","year":"2021","unstructured":"Luan, X. et al. Cyclophilin A is a key positive and negative feedback regulator within interleukin-6 trans-signaling pathway. FASEB J. 35, e21958 (2021).","journal-title":"FASEB J."},{"key":"4177_CR51","doi-asserted-by":"publisher","first-page":"109413","DOI":"10.1016\/j.cellsig.2019.109413","volume":"65","author":"Y Xie","year":"2020","unstructured":"Xie, Y., Li, X. & Ge, J. STAT3\u2212CyPA signaling pathway in endothelial cell apoptosis. Cell. Signal. 65, 109413 (2020).","journal-title":"Cell. Signal."},{"key":"4177_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra, T. & Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3, 791\u2013800 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"4177_CR53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1083\/jcb.201709137","volume":"217","author":"C-HA Tang","year":"2018","unstructured":"Tang, C.-H. A. et al. Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. J. Cell Biol. 217, 1739\u20131755 (2018).","journal-title":"J. Cell Biol."},{"key":"4177_CR54","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2016-09-741348","volume":"129","author":"B Bujisic","year":"2017","unstructured":"Bujisic, B. et al. Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. Blood 129, 2420\u20132428 (2017).","journal-title":"Blood"},{"key":"4177_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-0716-1732-8_14","volume":"2378","author":"H Zhu","year":"2022","unstructured":"Zhu, H., Jiang, C., Kaufman, R. J., Li, H. & Singh, N. In vitro stimulation of IRE1\u03b1\/XBP1-deficient B cells with LPS. Methods Mol. Biol. 2378, 221\u2013231 (2022).","journal-title":"Methods Mol. Biol."},{"key":"4177_CR56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ijrobp.2021.08.037","volume":"112","author":"I Franiak-Pietryga","year":"2022","unstructured":"Franiak-Pietryga, I. et al. Activated B cells and plasma cells are resistant to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 112, 514\u2013528 (2022).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4177_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04151-1","volume":"21","author":"F Long","year":"2023","unstructured":"Long, F. et al. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. J. Transl. Med. 21, 298 (2023).","journal-title":"J. Transl. Med."},{"key":"4177_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44195-x","volume":"14","author":"NK Altorki","year":"2023","unstructured":"Altorki, N. K. et al. Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I\u2212III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nat. Commun. 14, 8435 (2023).","journal-title":"Nat. Commun."},{"key":"4177_CR59","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s43018-021-00245-1","volume":"2","author":"Y Ban","year":"2021","unstructured":"Ban, Y. et al. Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. Nat. Cancer 2, 919\u2013931 (2021).","journal-title":"Nat. Cancer"},{"key":"4177_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01218-y","volume":"15","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 15, 72 (2023).","journal-title":"Genome Med."},{"key":"4177_CR61","doi-asserted-by":"publisher","unstructured":"Gonzalez-Kozlova, E. (ed.) Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17393774 (2025).","DOI":"10.5281\/zenodo.17393774"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04177-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04177-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:41Z","timestamp":1774018961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04177-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4177"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04177-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G. reports other research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech and Takeda not related to this study. S.G. has served on a scientific advisory board for Taiho Pharmaceuticals. S.G. is a named co-inventor on an issued patent (US20190120845A1) for Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS), an mIHC technology to characterize tumors and treatment responses that is filed through the Icahn School of Medicine at Mount Sinai and currently remains unlicensed. M.M. serves on the scientific advisory board of and holds stock from Compugen Inc., Dynavax Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc. and Owkin Inc. M.M. also serves on the scientific advisory board of Innate Pharma Inc., DBV Inc. and Genenta Inc. M.M. receives funding for contracted research from Regeneron and Boerhinger Ingelheim. T.U.M. has served on advisory and\/or data safety monitoring boards for Rockefeller University, Regeneron, AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus and Astellas and has research grants from Regeneron, Bristol Myers Squibb, Merck and Boehringer Ingelheim. This technology was used to evaluate tissue in this study, and the results could impact the value of this technology. Finally, this study was partially funded by Regeneron. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}